Thursday 23 November 2017, 13:00 pm
Boardroom of Aix-Marseille University Faculty of Medicine
27 Boulevard Jean Moulin, 13 385 Marseille cedex 5
Immunotherapy is becoming a game-changer in the treatment of cancers, including one of the most serious: non-small-cell lung cancer (NSCLC). However to date, only 20% of these patients respond favorably to the first available immune-modulating antibodies: PD-1 immune checkpoint inhibitors.
An international team of researchers and clinicians from academia and industry and coordinated by Prof. Fabrice BARLESI gave itself 5 years to better understand, predict and overcome these resistances. Laureate of the third “University-Hospital Research in Health” call for projects of the program “Investments for the Future” , this major project, called PIONEER, is being launched on 23 November in Marseille.